ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Wednesday, November 16, 2016

9:00AM-10:30AM
Abstract Number: 3171
The Impact of Statin Use on Mortality in Systemic Autoimmune Rheumatic Diseases
Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Damage and Morbidity
9:00AM-10:30AM
Abstract Number: 3150
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Rheumatoid Arthritis – Clinical Aspects VI: Management of Early Rheumatoid Arthritis
9:00AM-10:30AM
Abstract Number: 3129
The Pharmacokinetics of Oxypurinol in Patients Treated with Hemodialysis and Allopurinol
Metabolic and Crystal Arthropathies II: Clinical Practice
9:00AM-10:30AM
Abstract Number: 3181
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis
Vasculitis IV: Diagnosis and Assessment of Disease Activity
9:00AM-10:30AM
Abstract Number: 3183
Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial 
Vasculitis IV: Diagnosis and Assessment of Disease Activity
9:00AM-10:30AM
Abstract Number: 3167
Total and Glucocorticoid-Related Damage Accrual in the Systemic Lupus International Collaborating Clinics Inception Cohort
Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Damage and Morbidity
9:00AM-10:30AM
Abstract Number: 3127
Ultrasound Evaluation of the Achilles Tendon in Tophaceous Gout: A Case-Control Study
Metabolic and Crystal Arthropathies II: Clinical Practice
9:00AM-10:30AM
Abstract Number: 3180
Utility of Measurements of Urinary Soluble CD163 & MCP-1 in the Identification of Subtle Renal Flares in ANCA-Associated Vasculitis
Vasculitis IV: Diagnosis and Assessment of Disease Activity
9:00AM-10:30AM
Abstract Number: 3159
Validation of MRI Structural Lesions Using Computed Tomography in Patients with Axial Spondyloarthritis
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V: Imaging of Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 3158
What Predicts Absence of Spinal Damage in Patients with Spondyloarthritis after Prolonged Follow up?
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V: Imaging of Spondyloarthritis
9:00AM-10:30AM
Abstract Number: 3155
Zygapophyseal Joint Fusion in Ankylosing Spondylitis Assessed Using Computed Tomography: Associations with Syndesmophytes and Spinal Motion
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment V: Imaging of Spondyloarthritis
11:00AM-12:30PM
Abstract Number: 3210
10+ Years’ Follow-up of a Danish 2-Year Treat-to-Target RCT in Patients with Early Rheumatoid Arthritis: Baseline Predictors of Functional and Radiographic Outcomes
Rheumatoid Arthritis – Clinical Aspects VII: The Impact of Treating to Target
11:00AM-12:30PM
Abstract Number: 3196
A Natural Language Processing System Can Capture Rheumatoid Arthritis Disease Activity Measures in US Veterans Across Multiple Sites
Health Services Research II
11:00AM-12:30PM
Abstract Number: 3255
A Randomized Trial of Automated Telephone-Linked Communication to Improve Exercise Adherence for a Progressive Resistance Training Program in People with Knee Osteoarthritis
ARHP VI: Rehabilitation Sciences
11:00AM-12:30PM
Abstract Number: 3219
Altered microRNA Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals the Pathogenic Profile of These Cells. Effect of Biological Therapies
Rheumatoid Arthritis – Human Etiology and Pathogenesis II
  • «Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 10
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology